I agree that it’s difficult to sort out the combined numbers for TDOC/LVGO.
But the overall picture indicates organic revenue growth of 79% for 2020 and guidance for 40-43% organic revenue growth (combined 1.4 billion increasing to 1.95-2 billion) in 2021. That sounds low but seems likely to be conservative. I would anticipate at least 45-50% with beats. It’s also important to remember this is in comparison to some transitory pandemic bumps in 2020. Guidance is a bit of guesswork at this transitional time in healthcare. Per conference call comments, cross-selling is reportedly going well. I would not be surprised if the guidance ends up being very conservative and I’m happy they are confident in at least this type of growth as the pandemic eases. With the after hours drop, this company is valued at about 17 times this year’s projected sales with an outlook for sustainable superior longer term growth. This seems reasonable to me.
Dave
Long TDOC